pantoprazole Side Effects
Also known as: Protonix
Analysis of 240,800 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
240,800
Death-Related
27,099
11.3% of reports
Hospitalizations
111,504
46.3% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 27,099 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 8,323 |
| PNEUMONIA | 2,343 |
| OFF LABEL USE | 2,310 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2,285 |
| DYSPNOEA | 2,148 |
| DIARRHOEA | 2,131 |
| FATIGUE | 2,130 |
| VOMITING | 1,931 |
| PYREXIA | 1,776 |
| ASTHENIA | 1,773 |
| NAUSEA | 1,748 |
| ACUTE KIDNEY INJURY | 1,726 |
| PAIN | 1,693 |
| HYPERTENSION | 1,613 |
| RASH | 1,584 |
| CONDITION AGGRAVATED | 1,560 |
| CONFUSIONAL STATE | 1,501 |
| DECREASED APPETITE | 1,497 |
| HEADACHE | 1,444 |
| ARTHRALGIA | 1,431 |
Reactions in Hospitalization Reports
Top reactions in 111,504 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 9,997 |
| NAUSEA | 8,886 |
| FATIGUE | 8,686 |
| DIARRHOEA | 8,583 |
| PNEUMONIA | 7,629 |
| VOMITING | 7,598 |
| PYREXIA | 7,404 |
| OFF LABEL USE | 7,393 |
| PAIN | 6,616 |
| ASTHENIA | 6,614 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 6,182 |
| FALL | 5,878 |
| ANAEMIA | 5,539 |
| DRUG INEFFECTIVE | 5,477 |
| HEADACHE | 5,467 |
| ACUTE KIDNEY INJURY | 5,453 |
| DIZZINESS | 5,316 |
| ARTHRALGIA | 4,987 |
| ABDOMINAL PAIN | 4,983 |
| CONDITION AGGRAVATED | 4,976 |
Nearby — Related Medications
What the FAERS Data Reveals About pantoprazole Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 240,800 voluntary reports linked to pantoprazole and its brand equivalents (Protonix), spanning 2003 through 2025. Of those, 27,099 (11.3%) listed death as an outcome and 111,504 (46.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 58% were female and 42% male; age distribution skews toward 45-64, with 57,494 reports in that bracket. The single most reported reaction is fatigue with 19,879 submissions, followed by off label use and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.